Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet